Amgen And Sanofi Settle Repatha IP Dispute After Supreme Court Battle

By Editorial Team

Amgen Inc. and Sanofi have reached a settlement in their patent litigation concerning rival cholesterol drugs Repatha and Praluent. This resolution comes more than two years after the companies faced off at the U.S. Supreme Court, as confirmed by Sanofi on Monday.

The legal battle between Amgen and Sanofi over their cholesterol medications has finally come to an end with this settlement, marking a significant development in the pharmaceutical industry.

Details of the settlement agreement, including any financial terms or licensing agreements, have not been disclosed publicly at this time.

Both companies have been engaged in a lengthy and complex legal dispute over the patents related to Repatha and Praluent, which are used in the treatment of high cholesterol. The settlement brings an end to this prolonged litigation, providing clarity and resolution for both parties.

Amgen and Sanofi’s decision to settle the intellectual property dispute reflects a strategic move to avoid further legal costs and uncertainties associated with prolonged litigation.

The resolution of this case highlights the importance of intellectual property rights in the pharmaceutical sector and the significance of protecting innovations and investments in drug development.

For more updates on legal developments and industry news, stay tuned to Law360 for the latest updates.